Dendreon Corp

Dendreon — Merger or Acquisition (April 2003)

42 slides from Dendreon's merger presentation, Apr 15, 2003

  1. Slide 1: Building a Premier Biotechnology Company

    DENDREON CORPORATION CORVAS INTERNATIONAL Building a Premier Biotechnology Company

  2. Slide 2: Forward-Looking Statement Disclaimer

    Forward-Looking Statement Disclaimer This presentation includes forward-looking statements, including statements about Dendreon's proposed acquisition of Corvas, post-closing business synergies and product opportunities, and product development and commercialization. Actual results may differ materi

  3. Slide 3: Additional Information About the Acquisition and Where to Find It

    Additional Information About the Acquisition and Where to Find It Dendreon and Corvas have filed with the Securities and Exchange Commission (“SEC”) a Registration Statement on Form S-4, which contains a preliminary joint proxy statement/prospectus with respect to the combination and other relevant

  4. Slide 4: Dendreon Corporation

    Dendreon Corporation Developing targeted therapies for the treatment of cancer o Immunotherapeutic cancer programs - Provenge®, MylovengeTM, APC8024, Trp-p8, NY-ESO, CEA, MN, Telomerase o Monoclonal antibodies and small molecules - Trp-p8, DN1921, DN1924 o Industry leading collaborators - Genentech,

  5. Slide 5: Momentum Continues in 2003

    Momentum Continues in 2003 Corvas Acquisition o Stock for stock transaction o Valued at $73 M, based on Dendreon stock price as of 2/24/03, an 83% premium to Corvas' stock price as of the same date o Dendreon will own 68.3% and Corvas stockholders will own 31.7%, based on current capitalization o Co

  6. Slide 6: Combining Strengths

    Combining Strengths Technology o Broad oncology portfolio covering 4 platforms o 5 ongoing clinical programs o Enhanced intellectual property estate, 87 issued U.S. patents o Small molecule, medicinal chemistry expertise Operations o Experienced management team o Clinical development expertise o Res

  7. Slide 7: Preclinical Synergies in Oncology

    Preclinical Synergies in Oncology Vaccine Targets Antibodies Small Molecules Prodrug Program NY-ESO Trp-p8 Trp-p8 uPA CEA DN1924 Urokinase (uPA) Inhibitors Other Serine Proteases MN DN1921 (autoimmune diseases) Matriptase Inhibitors Telomerase Serine Protease Inhibitors Trp-p8 DVDN CVAS

  8. Slide 8: Advanced Clinical Trial Pipeline

    Advanced Clinical Trial Pipeline Product / Target Phase 1 Phase 2 Phase 3 Provenge(®) Androgen Independent Prostate Cancer D9901 D9902 Androgen Dependent Prostate Cancer Mylovenge(TM) Multiple Myeloma rNAPc2 Acute Coronary Syndromes APC8024 Breast, Ovarian, Colon Cancers DVDN CVAS

  9. Slide 9: Leading Cancer Vaccine Platform

    Leading Cancer Vaccine Platform Well validated and well characterized antigen targets manufactured as recombinant proteins Proprietary Antigen Delivery Cassette TM technology Induces strong and reproducible immune responses

  10. Slide 10: Provenge Phase 3 Trial (D9901)

    Provenge® Phase 3 Trial (D9901) (Chart) First randomized, double blind, placebo controlled Phase 3 study of a cancer vaccine Advanced androgen independent prostate cancer patients No existing treatment options (except palliatives for pain) Primary endpoint - Median time to objective disease progress

  11. Slide 11: Primary Efficacy Analysis (ITT)

    Primary Efficacy Analysis (ITT) Time from randomization to disease progression (Chart) Phase 3 Trial #D9901

  12. Slide 12: Gleason Score

    Gleason Score o Routinely performed prostate grading system - Histologic measure of aggressiveness of tumor - Patients with score of < 7 tend to have better prognosis o Majority (75%) of androgen independent patients have a score of 7 or less o Pre-specified subgroup for analysis o Single most impor

  13. Slide 13: Efficacy Analysis: Gleason < 7

    Efficacy Analysis: Gleason < 7 Time to objective disease progression (Kaplan-Meier method): Primary Efficacy Analysis, Gleason Score < 7, Intent-to-Treat Patients (Chart) Phase 3 Trial #D9901

  14. Slide 14: Comparison of Gleason Subgroups

    Comparison of Gleason Subgroups Subgroup Analysis: Gleason < 7 (Chart) Subgroup Analysis: Gleason > 8 (Chart) Phase 3 Trial #D9901

  15. Slide 15: Progression Analysis: Gleason < 7

    Progression Analysis: Gleason < 7 Time to Progression (weeks) Provenge Placebo (N=50) (N=25) Treatment Effect Median 16.0 9.0 1.78 Progression Free Survival Rate (percent) Provenge Placebo Treatment Effect Months 34.7 4.0 8.7 17.7 4.0 4.4 10.1 0 >10.1 6.7 0 > 6.7 Phase 3 Trial #D9901

  16. Slide 16: Secondary Endpoint

    Secondary Endpoint Time to Onset of Disease-Related Pain (Gleason < 7 and > 8) Gleason < 7 (Chart) Gleason > 8 (Chart) Phase 3 Trial #D9901

  17. Slide 17: Provenge Very Well Tolerated

    Provenge Very Well Tolerated* APC8015 (n=82) Placebo (n=45) Median Duration (days) Event [n(%)] Rigor 49 (59.8) 3 (6.7) 1.0 Pyrexia 24 (29.3) 1 (2.2) 2.0 Headache NOS 11 (13.4) 1 (2.2) 1.0 Paresthesia 11 (13.4) 1 (2.2) 2.0 Dyspnea 9 (11.0) 1 (2.2) 1.0 Number (%) of patients with Adverse Events *Occu

  18. Slide 18: Results of Recent FDA Discussions

    Results of Recent FDA Discussions o Recognized that D9901 data is promising and would be supportive to filing o Patients with Gleason score < 7 are relevant population on which to base approval o Modified existing D9902 trial (D9902B) will provide basis for registration o Approximately 275 patients

  19. Slide 19: Worldwide Prostate Cancer Therapeutic Sales

    Worldwide Prostate Cancer Therapeutic Sales $2.76 billion in 2001 (Chart) Source: Med Ad News; IMS Health

  20. Slide 20: Provenge Collaboration Discussions

    Provenge Collaboration Discussions o Large market with unmet need o Receipt of 9901 data and agreement from FDA have driven high level of interest in Provenge o Competitive process o Will be structured as co-development and co-promotion agreement o Global agreement minus Asia and Oceania

  21. Slide 21: APC8024 Phase 1 Trials

    APC8024 Phase 1 Trials Patient Population o Advanced, metastatic breast, ovarian and colon cancer patients o Her-2 positive o Failed all conventional therapies including Herceptin Endpoints o Safety o Clinical response o Immune response

  22. Slide 22: D2000-2 Clinical Response

    D2000-2 Clinical Response Status of 11 patients evaluated Stable 5 (45%) Partial Response* 1 (9%) * As determined by a more than 50% reduction in tumor volume

  23. Slide 23: Dendreon & Genentech Trp-p8 Collaboration

    Dendreon & Genentech Trp-p8 Collaboration

  24. Slide 24: Trp-p8 Characteristics

    Trp-p8 Characteristics o Trans-membrane voltage gated Ca2+ channel o Over-expressed in breast, prostate, lung and colon cancers as well as hyperplastic prostate o Multiple therapeutic opportunities - Vaccines - Monoclonal antibodies - Small molecules References: U.S. Patent 6,194,152: Prostate tumor

  25. Slide 25: Trp-p8 Expression Restricted to the Prostate in Normal Tissue

    In Normal Human Tissue, Trp-p8 Expression is Restricted to the Prostate (Chart)

  26. Slide 26: Trp-p8 Detected in Primary Cancer Samples

    Trp-p8 is Detected in Primary Cancer Samples by In Situ Hybridization Tissue type Prostate Adeno Ca Breast Adeno Ca Melanoma Colorectal Adeno Ca Lung Ca Number of samples positive/studied Normal Breast Tissue Breast/CA RNA Tissue (Chart) Normal Colon Tissue Colon/CA RNA Tissue (Chart)

  27. Slide 27: Trp-p8 Architecture

    Trp-p8 -— Architecture

  28. Slide 28: Trp-p8 Therapeutics

    Trp-p8 -Therapeutics

  29. Slide 29: Genentech Trp-p8 Collaboration

    Genentech Trp-p8 Collaboration o Structured as a co-development, co-promotion agreement with profit sharing rights in the U.S. o Significant upfront and milestone payments o Genentech responsible for manufacturing and funds majority of manufacturing and clinical trial costs o Leverage Corvas' medici

  30. Slide 30: Collaboration Milestones

    Collaboration Milestones o Equity purchases and cash milestone payments o Milestone Events - At deal signing - Drug candidate identification - IND filing - Clinical trial milestones - BLA submission - BLA approvals o Total milestone payments could exceed $110 Million

  31. Slide 31: Corvas Oncology Programs

    Corvas Oncology Programs DENDREON CORPORATION CORVAS INTERNATIONAL

  32. Slide 32: Serine Protease Cancer Programs

    Serine Protease Cancer Programs [CHART] Relevant for prostate cancer Most well known is PSA Provide a number of therapeutic opportunities –Inhibition with small molecules or monoclonal antibodies –As a target for monoclonal antibodies and therapeutic vaccines –Leverage enzymatic activity for deliver

  33. Slide 33: Protease Activated Cancer Therapy (PACT) Program

    Protease Activated Cancer Therapy (PACT) Program [CHART]

  34. Slide 34: CVS-10290 PK in DU145 Bearing Nude Mice

    CVS-10290 PK - Acute dose of 25mg/kg CVS-10290, IP in DU145 bearing nude mice Dox peaks at 4 hours in tumors At 24 hours dox is still detectable in tumors [CHART]

  35. Slide 35: CVS-10290 Efficacy Study Q1dx5

    CVS-10290 Efficacy Study Q1dx5 [CHART] Dose Group max group % body weight loss % Tumor growth inhibition t test (p-value) Control - Dox 1.0 mg/kg -12% 0.1980 3/10 toxic deaths CVS-10290 20mg/kg -9% 0.0112

  36. Slide 36: Corvas Cardiovascular Program

    Corvas Cardiovascular Program DENDREON CORPORATION CORVAS INTERNATIONAL

  37. Slide 37: rNAPc2 Potent Anticoagulant

    rNAPc2 Potent Anticoagulant Acts at initiation of coagulation cascade by blocking Tissue Factor/Factor VIIa complex Produces sustained suppression of thrombin generation - - a key element in acute coronary syndrome (ACS) Potent and prolonged duration of action May complement downstream products (hep

  38. Slide 38: ANTHEM TIMI Phase 2 Trial Design

    ANTHEM TIMI 32 Phase 2 Trial design [CHART] Part 1 - Dose Escalation Initial safety experience Go or no go decision 2H 2003 [CHART] Part 2 - Dose Ranging Evaluate safety & efficacy Seek Collaborator [CHART] Part 3 - Dose Confirmation Select dose for Phase 3 Conducted with Collaborator

  39. Slide 39: Pro Forma Balance Sheet

    Pro Forma Balance Sheet Year Ending Dec. 31, 2002 ($ in millions) Pro Forma 2002 Cash, cash equivalents, short-term & long-term investments $145.5 Working capital Total assets 158.3 Total stockholder's equity 119.9

  40. Slide 40: Expected Milestones and News Flow

    Expected Milestones and News Flow Type 2003 2004 2005 Clinical Data Presentations at upcoming scientific meetings Regulatory Fast track designation -- Provenge Preclinical Milestone Trp-p8 Mab lead selection and DNA milestone payment Clinical Trials Complete Phase II Mylovenge studies Clinical Trial

  41. Slide 41: The New Dendreon

    The New Dendreon Creating a top tier biotech company Validated therapeutic cancer platform - Near-term market opportunities - Significant clinical benefit demonstrated with Provenge® Broad portfolio includes monoclonal antibodies, small molecules, and prodrugs Industry leading partners Capitalized t

  42. Slide 42: Dendreon Corporation

    DENDREON CORPORATION ©Dendreon 2003

Dendreon — Merger or Acquisition (April 2003) on 6ix